ATC Group: A10BD Combinations of oral blood glucose lowering drugs

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A10BD in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A10 Drugs used in diabetes
3 A10B Blood glucose lowering drugs, excl. insulins
4 A10BD Combinations of oral blood glucose lowering drugs

Group A10BD contents

Code Title
A10BD01 Phenformin and sulfonamides
A10BD02 Metformin and sulfonamides
A10BD03 Metformin and rosiglitazone
A10BD04 Glimepiride and rosiglitazone
A10BD05 Metformin and pioglitazone
A10BD06 Glimepiride and pioglitazone
A10BD07 Metformin and sitagliptin
A10BD08 Metformin and vildagliptin
A10BD09 Pioglitazone and alogliptin
A10BD10 Metformin and saxagliptin
A10BD11 Metformin and linagliptin
A10BD12
A10BD13 Metformin and alogliptin
A10BD14
A10BD15 Metformin and dapagliflozin
A10BD16 Metformin and canagliflozin
A10BD17
A10BD18
A10BD19 Linagliptin and empagliflozin
A10BD21 Saxagliptin and dapagliflozin
A10BD22
A10BD23 Metformin and ertugliflozin
A10BD24
A10BD25
A10BD26
A10BD27
A10BD28
A10BD29

Active ingredients in A10BD

Active Ingredient Description
Linagliptin and Empagliflozin

Antihyperglycaemic medicinal products with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes. Linagliptin is an inhibitor of DPP-4 an enzyme which is involved in the inactivation of the incretin hormones GLP-1 and GIP (glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide). Empagliflozin is a reversible, highly potent (IC50 of 1.3 nmol) and selective competitive inhibitor of SGLT2.

Metformin and Alogliptin
Metformin and Canagliflozin

Combination of two oral glucose-lowering medicinal products with different and complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: canagliflozin, an inhibitor of SGLT2 transporter, and metformin hydrochloride, a member of the biguanide class.

Metformin and Dapagliflozin

Combination fo two anti-hyperglycaemic medicinal products with different and complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: dapagliflozin, a SGLT2 inhibitor, and metformin hydrochloride, a member of the biguanide class.

Metformin and Empagliflozin

Combination of two antihyperglycaemic medicinal products with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: empagliflozin, an inhibitor of sodium-glucose co-transporter 2 (SGLT2), and metformin hydrochloride, a member of the biguanide class.

Metformin and Ertugliflozin

Combination of two anti-hyperglycaemic agents with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: ertugliflozin, a SGLT2 inhibitor, and metformin, a member of the biguanide class.

Metformin and Linagliptin

Combination of two antihyperglycaemic medicinal products with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: linagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, and metformin hydrochloride, a member of the biguanide class.

Metformin and Pioglitazone

Combination of two antihyperglycaemic active substances with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes mellitus: pioglitazone, a member of the thiazolidinedione class and metformin hydrochloride, a member of the biguanide class. Thiazolidinediones act primarily by reducing insulin resistance and biguanides act primarily by decreasing endogenous hepatic glucose production.

Metformin and Rosiglitazone

Combination of two antihyperglycaemic agents with complimentary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: rosiglitazone, a member of the thiazolidinedione class and metformin, a member of the biguanide class. Thiazolidinediones act primarily by reducing insulin resistance and biguanides act primarily by decreasing endogenous hepatic glucose production.

Metformin and Saxagliptin

Combination of two antihyperglycaemic medicinal products with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: saxagliptin, a dipeptidyl peptidase 4 (DPP4) inhibitor, and metformin hydrochloride, a member of the biguanide class.

Metformin and Sitagliptin

Combination of two antihyperglycaemic medicinal products with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: sitagliptin phosphate, a dipeptidyl peptidase 4 (DPP-4) inhibitor, and metformin hydrochloride, a member of the biguanide class.

Metformin and Vildagliptin

Combination of two antihyperglycaemic agents with complimentary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: vildagliptin, a member of the islet enhancer class, and metformin hydrochloride, a member of the biguanide class.

Pioglitazone and Alogliptin

Combination of two antihyperglycaemic medicinal products with complementary and distinct mechanisms of action to improve glycaemic control in patients with type 2 diabetes mellitus: alogliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor, and pioglitazone, a member of the thiazolidinedione class.

Saxagliptin and Dapagliflozin

Combination of saxagliptin and dapagliflozin with complementary mechanisms of action to improve glycaemic control. Saxagliptin, through the selective inhibition of dipeptidyl peptidase-4 (DPP-4), enhances glucose-mediated insulin secretion (incretin effect). Dapagliflozin, a selective inhibitor of sodium-glucose co-transporter 2 (SGLT2), inhibits renal glucose reabsorption independently of insulin. Actions of both medicinal products are regulated by the plasma glucose level.

Sitagliptin and Ertugliflozin

Combination of two antihyperglycaemic agents with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: ertugliflozin, a SGLT2 inhibitor, and sitagliptin phosphate, a DPP-4 inhibitor.

Related product monographs

Title Information Source Document Type  
AVANDAMET Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
COMPETACT Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
EUCREAS Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
GALVUS MET Film-coated tablet Health Products Regulatory Authority (ZA) MPI, Generic
GLUCOVANCE Film-coated tablet Web Search MPI, EU: SmPC
GLYXAMBI Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
INCRESYNC Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
JALRAMET Film-coated tablet Health Products Regulatory Authority (ZA) MPI, Generic
JANUMET Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
JENTADUETO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
KOMBIGLYZE XR Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
KOMBOGLYZE Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
QTERN Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
SEGLUROMET Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
STEGLUJAN Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
SYNJARDY Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
VIPDOMET Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
VOKANAMET Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
XIGDUO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC